Somatic insertions/deletions in the calreticulin gene have recently been discovered as causative alterations in myeloproliferative neoplasms. A combination of qualitative and quantitative allelespecific polymerase chain reaction, fragment-sizing, high resolution melting and Sangersequencing was applied for the detection of three driver mutations (in Janus kinase 2, calreticulin and myeloproliferative leukaemia virus oncogene genes) in 289 essential thrombocythaemia and 99 primary myelofibrosis cases. In essential thrombocythaemia, 154 (53%) Janus kinase 2 V617F, 96 (33%) calreticulin, 9 (3%) myeloproliferative leukaemia virus oncogene gene mutation positive and 30 triple-negative (11%); while in primary myelofibrosis 56 (57%) V617F, 25 (25%) calreticulin, 7 (7%) myeloproliferative leukaemia virus oncogene gene mutation positive and 11 (11%) triple-negative cases were identified. Calreticulin mutation positive patients were younger, had higher platelet counts compared to Janus kinase 2 mutation positive counterparts. Calreticulin mutation positive patients with essential thrombocythaemia showed lower risk for venous thrombosis, but no difference in overall survival. Calreticulin mutation positive patients with primary myelofibrosis showed better overall survival compared to the Janus kinase 2 mutation positive (p=0.04) or triple-negative cases (p=0.01). Type 2 calreticulin mutation occurred more frequently in essential thrombocythaemia compared to primary myelofibrosis (p=0.049). In essential thrombocythaemia, calreticulin mutational load was higher than Janus kinase 2 mutational load (p<0.001), and increased gradually in advanced stages.
INTRODUCTION
The characterization of the genetic background of BCR-ABL1 negative chronic myeloproliferative neoplasms (MPN) advanced with a giant leap by the discovery of the Janus kinase 2 (JAK2) kinase V617F mutation in the three classic MPNs: 90-95% of polycythaemia vera (PV), 40-60% of essential thrombocythaemia (ET) and primary myelofibrosis (PMF), [1] [2] [3] [4] resulting in the inclusion of V617F mutation screening in the diagnostic criteria.
5 JAK2exon 12 mutations occur in rare cases of V617F-negative PV allowing a close to perfect coverage by specific genetic alterations in PV. 6, 7 On the other hand, clinicians continue to face challenges during the diagnosis of JAK2 mutation (JAK2 mut ) negative ET and PMF. Moving the field very close to full coverage, in two parallel seminal discoveries, Klampfl et al. 8 and Nangalia et al. 9 recently described somatic, recurrent insertions/deletions exclusively affecting exon 9 of the calreticulin (CALR) gene. Affecting the same driver pathway, CALR mutations were mutually exclusive with JAK2 V617F or myeloproliferative leukaemia virus oncogene gene (MPL)
mutations. In a plethora of subsequent studies published within 3 months, the initial findings were confirmed and extended focusing on the clinical correlates. [10] [11] [12] [13] Several additional studies described low frequencies of CALR mutations in different MPN-related diseases, but not in other haematological disease entities. 8, 9, [14] [15] [16] [17] [18] As a result of the discovery of CALR mutations, the definite molecular diagnostics have become available in 75-90% of clonal MPNs. For the introduction of CALR mutation screening into the routine clinical practice, it is essential to characterize the potential effects of CALR mutations on disease phenotype and progression in several independent cohorts. The aim of our study was to apply a complex array of molecular techniques to identify driver mutations. We aimed to confirm previous associations between the presence of acquired genetic alterations and clinical characteristics in a large, independent MPN-cohort. In addition, our purpose was to systematically analyse the roles of particular CALR mutation types and load.
METHODS

Subjects
Our study population consisted of 603 patients with BCR-ABL1 negative MPN (260 males/343 females, median age: 60, range: 10-94 years) diagnosed between 1974 and 2013, as an extension of those published earlier. 19, 20 According to WHO 2008 criteria, 215 patients suffered from JAK2 V617F positive polycythaemia vera (PV), 289 patients from essential thrombocythaemia (ET) and 99 patients from primary myelofibrosis (PMF were recorded if they were present at diagnosis or during follow up. The median follow up was 5.7 (range: 0-40 years). All participants signed informed consents. The study was approved by the Hungarian National Ethics Committee.
Detection of driver somatic mutations
All analyses were performed using genomic DNA isolated from peripheral blood or bone marrow. For a subset of patients, sampling and diagnosis ascertainment happened within 1 year.
In some analyses, these cases were considered separately as the ones best reflecting the patient condition at diagnosis.
All MPN-patients were screened for JAK2 V617F (c.1849G>T) by allele-specific PCR. Regarding outcome parameters, overall survival (OS) was analysed in ET ( Figure 1A ) and PMF ( Figure 1B ) stratified according to different driver mutations initially by univariate KaplanMeier approach. Out of the 289 ET patients, 261 cases had appropriate follow-up information [JAK2 mut (n=150), CALR mut (n=85) and triple-negative (n=26) subgroups]. As shown on Figure   1A , no differences were detected in OS upon univariate analyses (p=0.846). In PMF (n=87), the subgroups were the following: JAK2 mut (n=55), CALR mut (n=21) and triple-negative (n=11). In contrast to ET, the overall comparison resulted in p=0.023 ( Figure 1B) Table 2 ). Similar analyses were not feasible for the PMF cohort due to the low (n=3) representation of type 2 CALR mutation. To investigate the potential effects of CALR mutational load, we divided CALR mut ET patients with available sample within 1 year from diagnosis (n=31) into two subgroups according to CALR mut load with the cut off value of 38.5%, which was the median of CALR mutational load of all ET-patients in the study (n=20 below the cut off and n=11 above the cut off, see Table 3 ). 
Subgroup analyses in patient cohorts
DISCUSSION
We set up a sequential application of different molecular techniques to identify the driver mutations in a large cohort of MPN patients, noting that JAK2 V617F, CALR and MPL mutations were described as mutually exclusive driver mutations in the first studies. 8, 9 Concurrent JAK2
and CALR mutations were reported only in two individuals in subsequent studies. 13, 14 Similarly to earlier observations on different MPN cohorts, [8] [9] [10] 13 we demonstrated a similar frequency of CALR mutation in an independent group of MPN-patients with a high frequency (121/162, 75%)
among JAK2 V617F and MPL-negative ET-patients leaving a small cohort of triple-negative patients lacking a disease causing genetic marker.
In our previous study comparing the clinical characteristics of JAK2 mut and JAK2 neg MPN patients (n=328), 19 we already noticed a female predominance, older age at presentation, higher p=0.03) in a smaller ET-cohort. 9 In a large study, the incidence of myelofibrotic transformation was 7 (95% CI 3-13) in CALR mut vs. In ET, we did not find differences in OS affected by the presence of specific driver mutation. Similarly to ET and previous reports, 8, 13 younger age at disease onset and elevated PLT counts were found to characterize our CALR mut PMF cohort. Our observations in PMF were in good agreement with previous reports, 8, 13 indicating a significant beneficial effect of the presence of CALR mut on OS compared to JAK2 mut . In our dataset, the differences were further substantiated by pairwise comparisons in a multivariate (with age added as covariate) Cox model indicating a trend towards better survival in CALR mut compared to JAK2 mut and a significantly better survival between CALR mut and triple-negative MF patients. In addition, the decreased leukaemia-free survival in triple-negative PMF reported by Tefferi et al., 13 was in line with the increased acute leukaemic transformation rate of our triple-negative PMF cases (see Table 2 ). Recently, a set of gene mutations were described as detrimental in PMF. The presence of any "high molecular risk" mutations affecting ASXL1, EZH2, SRSF2, IDH1/2 genes predicted shorter overall survival and increased risk of leukemic transformation. CALR mutation proved to be an independent protective factor for survival in PMF. 24 ASXL1 mutations, as most frequent detrimental mutations, were reported to occur with similar frequency in JAK2 mut , CALR mut or in triplenegative PMF patients, 13 thus in our PMF-cohort, the survival benefit observed in the CALR mut patient group was unlikely to result from the uneven distribution of ASXL1 mutation. The presence of CALR mut in PMF may affect prognostication and should be incorporated in the scoring system as recently suggested. 25, 26 Our data regarding the frequencies of type 1 and type 2 CALR mut in ET and in PMF were in good agreement with previous cohorts for ET [8] [9] [10] 12 and for PMF. 8, 13 The asymmetric distribution of different types of CALR mut comparing ET to PMF, i.e. the relatively lower frequency of type 2 CALR mut in PMF was in line with data from Klampfl et al. 8 They also observed a decreased (21/105, 20%) relative proportion of type 2 mutant cases among PMFpatients compared to ET (74/195, 38%). The profound differences in the CALR protein structure may explain this asymmetric distribution and may imply slight differences in the pathogenic effects of the respective variants. The observed asymmetric distribution prompted us to systematically analyse clinical and outcome differences in ET according to CALR mut type with key finding as older age at diagnosis, increased PLT counts and more frequent application of clear trend of increase in parallel with the appearance of more severe phenotypes of MPN.
Campbell et al. 28 suggested that JAK2 V617F mutated ET, PV and post-ET/PV-MF or PMF formed a biological continuum, where the different MPN phenotypes determined by JAK2 V617F allele burden modified by other environmental and inherited factors. The increasing JAK2 V617F allele burden through ET-PV-MF phenotypes was later confirmed in several studies, [29] [30] [31] and also in a transgenic mouse model. 32 
